This discussion explores the positioning of IBD therapies beyond anti-TNF agents, emphasizing the challenges of precision medicine, the importance of optimizing conventional treatments, and the need for individualized decision-making in the absence of head-to-head trial data.
- Precision medicine in IBD has underdelivered despite a decade of research; molecular profiling and AI-assisted treatment selection remain expensive, unvalidated, and not yet practical for routine clinical use
- When patients lose response to anti-TNF therapy, clinicians must first rule out infections, C. difficile, CMV, strictures, and other complications before switching drug class; drug level and antibody testing guides whether to switch within or out of class
- Treatment decisions after anti-TNF failure require individualized assessment of disease phenotype, extraintestinal manifestations, patient preferences, and drug characteristics, as guidelines cannot rank therapies due to lack of head-to-head trials; network meta-analyses suggest JAK inhibitors perform well in this setting
- Conventional therapies remain underutilized: topical mesalamine should accompany every ulcerative colitis flare, high-dose mesalamine (over four grams) is preferred for induction, and azathioprine intolerance can often be managed by dose titration, switching to mercaptopurine, or adding allopurinol for hepatotoxicity
- Combination infliximab and azathioprine is the preferred first-line regimen for high-risk patients (young age, perianal or extensive Crohn's, deep colonic ulceration), while approximately one-third of Crohn's patients have mild disease that may be overtreated with advanced biologics
This summary was generated by an AI large language model based on the content transcript. It is for informational
purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional
expertise and the full clinical context when making clinical decisions.